The AHSN Network has supported many innovators to help advance our health and care system. Find out more about successful innovations supported by the NHS.
Find your nearest AHSN
HeartFlow FFRCT for estimating fractional flow reserve (FFR) from coronary CT angiography
Coronary heart disease (CHD) is the world’s number one killer, accounting for 15% of UK deaths in 2019¹. HeartFlow FFRCT analysis provides clinicians with a more efficient pathway for diagnosing CHD that combines simulation models and medical imaging data.
Placental Growth Factor (PlGF) based testing for pre-eclampsia
Pre-eclampsia (PE) affects approximately 3% of all pregnancies and is a serious cause of maternal and foetal morbidity. There is no definitive test to help diagnose PE and the only “cure” is delivery of the baby. High suspicion for the disease and a low threshold for admission places a considerable unnecessary burden on the system, something that PlGF based testing aims to alleviate.
gammaCore for cluster headache pain
GammaCore is a simple-to-use, handheld medical device that enables patients to self-administer discrete doses of non-invasive vagus nerve stimulation (nVNS) therapy to the neck.
Tamoxifen – Licensed repurposed therapies for use in managing breast cancer risk in people with a family history
Of 1000 women who appropriately take Tamoxifen as chemoprevention, 30 will be prevented from developing cancer over a 5-year period. The AAC is launching this project to promote awareness, among primary care clinicians, of prescribing Tamoxifen to reduce the chance of developing breast cancer for women with familial risk of breast cancer
FeNO testing for suspected asthma patients
FeNO (Fractional exhaled Nitric Oxide) testing alongside the recommended NICE diagnostic tests, will help enable more accurate diagnosis of asthma. Over 120,000 patients a year, 30% of the asthma population, are wrongly diagnosed and given inappropriate medication. Our project will look to reduce the use of steroids and improve diagnosis, enabling correct adjustments or the right medication to be prescribed. FeNO is indicative of the severity of airway inflammation.
Asthma Biologic precision medicines for the treatment of severe eosinophilic asthma
Less than 50% of severe asthma patients have eosinophil-driven disease (Wenzel2005) and Biologics are designed to control the number of eosinophil cells (Asthma UK). Only 10.8% of eligible severe asthma patients have access to biologic medicines today in the UK.Increasing the use of biologics appropriately would reduce use of Oral corticosteroids (OCS), associated with negative side effects, and exacerbations, causing 75,000 annual UK hospital admissions, each costing £1500.
Preventing prescribing errors in south London with PINCER
PINCER is the Pharmacist-led Information technology iNtervention for the reduction of Clinically important ERrors in medicines management.
High-sensitivity troponin tests for the early rule out of non-ST-segment elevation myocardial infarction (NSTEMI)
The improved accuracy of the high sensitivity test compared to the standard troponin test allows testing of troponin concentration and type (T or I) at 1-hour and/or 3-hours post ED presentation. This innovation adoption in both technology and pathway will greatly improve patient care and efficiency at ED, enabling patients to be sent home secure in the knowledge that a heart attack has not occurred while keeping beds free in ED.
Cladribine for treating relapsing–remitting multiple sclerosis
The UK multiple sclerosis (MS) population is expected to increase annually by 2.4%1. Cladribine offers an orally administered option for highly active relapsing-remitting MS, avoiding the need for infusions, and requires less frequent dosing and monitoring compared to other therapies.
Covid Oximetry @home and virtual ward
The HIN has been commissioned to support a drive to equip members and partners to offer the Covid Oximetry @home model. This comes as treatment of Covid-19 improves and evidence has shown that earlier detection of (silent) hypoxia at home could help further reduce mortality and morbidity.
Covid Oximetry @home and virtual ward
The Health Innovation Network (HIN) has been commissioned to support a drive to equip members and partners to offer the Covid Oximetry @home model. This comes as treatment of Covid-19 improves and evidence has shown that earlier detection of (silent) hypoxia at home could help further reduce mortality and morbidity.